KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Other Working Capital Changes (2016 - 2025)

West Pharmaceutical Services' Other Working Capital Changes history spans 17 years, with the latest figure at -$110.0 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 643.24% year-over-year to -$110.0 million; the TTM value through Dec 2025 reached -$108.1 million, down 1963.79%, while the annual FY2025 figure was -$108.1 million, 1963.79% down from the prior year.
  • Other Working Capital Changes for Q4 2025 was -$110.0 million at West Pharmaceutical Services, down from -$2.1 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $94.9 million in Q1 2021 and bottomed at -$185.4 million in Q4 2022.
  • The 5-year median for Other Working Capital Changes is $0.0 (2024), against an average of -$6.4 million.
  • The largest YoY upside for Other Working Capital Changes was 280.84% in 2021 against a maximum downside of 3382.61% in 2021.
  • A 5-year view of Other Working Capital Changes shows it stood at -$10.2 million in 2021, then tumbled by 1717.65% to -$185.4 million in 2022, then skyrocketed by 85.98% to -$26.0 million in 2023, then skyrocketed by 43.08% to -$14.8 million in 2024, then plummeted by 643.24% to -$110.0 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Other Working Capital Changes are -$110.0 million (Q4 2025), -$2.1 million (Q3 2025), and $4.1 million (Q2 2025).